Table 1.
Summary of recent studies with reports of HLC-derivation from human pluripotent stem cells
| Reference | Stem cell (cell line) | Differentiation method | Differentiation factors | Differentiation efficiency | ||
|---|---|---|---|---|---|---|
| % ALB +ve HLCs | % AAT +ve HLCs | Method of assessment | ||||
| Cai et al., 2007 [50] | hESC (H1, H9) | Monolayer, EB formation | AF V, AA, ITS, BMP2, FGF4, HGF, OSM, DEX | 70 | ND | ICC |
| Ek et al., 2007 [51] | hESC (SA002, SA002.5, SA167) | Monolayer | Proprietary differentiation medium, FGF2 | ND | ND | – |
| Söderdahl et al., 2007 [52] | hESC (SA001, SA002, SA002.5, AS034, SA121, and SA167) | Monolayer | Proprietary differentiation medium, bFGF | ND | ND | – |
| Hay et al., 2008 [53] | hESC (H1, H9) | Monolayer | AA, Wnt3a | 90 | ND | ICC |
| Shiraki et al., 2008 [54] | hESC (Khes-1) | Co-culture with M15 cell line | AA, BMP4, bFGF, HGF, DMSO, DEX, Ly294002 | 9 | ND | ICC |
| Agarwal et al.,2008 [55] | hESC (WA01, WA09) | Monolayer | AA, FGF4, HGF, BSA, OSM, DEX | 67.4 | 84.7 | ICC |
| Moore et al., 2009 [56] | hESC (H1) | Monolayer, EB formation | AA, Wnt3a, HGF, OSM, DEX | 72.8 | ND | ICC |
| Basma et al., 2009 [57] | hESC (H1) | Monolayer, EB formation | AA, FGF2, HGF, DMSO, DEX | 55.5 | ND | ICC |
| Song et al., 2009 [58] | hESC (H1), hiPSC | Monolayer | AF V, AA, ITS, BMP2, FGF4, OSM, DEX, KGF, B27 | 60 | ND | ICC |
| Duan et al., 2010 [59] | hESC (H9) | Monolayer | AA, sodium butyrate, BMP2, BMP4, FGF4, HGF DMSO, B27 | 75–90 | 64–75 | ICC, FACS, qRT-PCR, GFP reporter gene |
| Synnergren et al., 2010 [60] | hESC (SA002, SA167, SA461) | Monolayer | AA, ITS, FGF1, FGF2, BMP2, BMP4, HGF, OSM, DEX | ND | ND | – |
| Touboul et al., 2010 [61] | hESC (H9) | Monolayer | AA, BMP4,FGF2, FGF4, FGF10, HGF, EGF, retinoic acid, SB431542, Ly294002 | ND | ND | – |
| Brolén et al., 2010 [62] | hESC (SA001, SA002, SA002.5, SA167) | Monolayer | AA, BMP2, BMP4, FGF1, FGF2, HGF, OSM, DEX, Wnt3A | ND | ND | – |
| Ghodsizadeh et al., 2010 [82] | hiPSC | EB formation | AA, FGF2, HGF, DMSO, DEX | 50 | ND | FACS |
| Liu et al., 2010 [63] | hESC (WA01, WA09), hiPSC (*hPH-derived) | Monolayer | AA, FGF4, HGF, OSM, DEX | ND | ND | – |
| Si-Tayeb et al., 2010 [65] | hESC (H9), hiPSC | Monolayer | AA, BMP4, FGF2, OSM, B27 | 80 | ND | FACS |
| Sullivan et al., 2010 [81] | hiPSC | Monolayer | AA, HGF, Wnt3A, DMSO, OSM, hydrocortisone, tryptose phosphate broth, B27 | 70–90 | ND | ICC |
| Rashid et al., 2010 [83] | hiPSC | Monolayer | AA, BMP4, FGF2, HGF, OSM, Ly294002, CHIR99021 (GSK-3 inhibitor) | 83 | ND | FACS |
| Zhang et al., 2011 [66] | hESC (H9), hiPSC | Monolayer, EB formation | AA, BMP2, FGF4, HGF, KGF, OSM, DEX | 60–80 | 20 | ICC, FACS |
| Bone et al., 2011 [64] | hESC (Shef1, Shef3) | Monolayer | FGF4, HGF, OSM, DEX, 1 m (GSK-3 inhibitor) | ND | ND | – |
| Chen et al., 2012 [67] | hESC (H9), hiPSC | Monolayer | AA, ITS, HGF, Wnt3A, OSM, DMSO, DEX | ND | ND | – |
AA, activin A; AF V, albumin fraction V; bFGF, human recombinant basic FGF; BMP, bone morphogenic protein; BSA, bovine serum albumin; DEX, dexamethasone; DMSO, dimethyl sulfoxide; EGF, epidermal growth factor; FACS, fluorescence-activated cell sorting; FGF, fibroblast growth factor; GFP, green fluorescent protein; GSK, glycogen synthase kinase; HGF, hepatocyte growth factor; ICC, immunocytochemistry; ITS, insulin-transferrin-selenium; KGF, keratinocyte growth factor; ND, not determined; OSM, oncostatin M; qRT-PCR, quantitative real time polymerase chain reaction; Wnt3a, wingless-type MMTV integration site family, member 3a.